Real-World data reveals how breast cancer patients fare after initial therapy
NCT ID NCT06975371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study analyzed data from 1,415 patients with HR-positive, HER2-negative metastatic breast cancer in the United States. Researchers looked at what happened after patients progressed on their first-line treatment (endocrine therapy plus a CDK4/6 inhibitor) and started a second-line therapy. The goal was to understand real-world progression-free survival and overall survival using the Flatiron Health Database.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flatiron Health, Inc
New York, New York, 10013, United States